![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Says Eli Lilly’s Breast Cancer Treatment Isn’t Cost-Effective
NICE Says Eli Lilly’s Breast Cancer Treatment Isn’t Cost-Effective
![NICE-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/NICE-logo.gif?t=1604717099&width=430)
October 29, 2018
NICE did not recommend Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) for use by the UK’s National Health Service as an endocrine-based therapy for adults with breast cancer.
The drug appeared to work as well as other first treatments for locally advanced or metastatic, hormone receptor-positive, HER2-negative breast cancer, but NICE said it wasn’t cost-effective compared to other treatments that have already been granted approval on NHS.
Eli Lilly has not publicly disclosed the drug’s price.
Upcoming Events
-
21Oct